Gyre Therapeutics (NASDAQ:GYRE) Sets New 1-Year Low – Time to Sell?

Gyre Therapeutics, Inc. (NASDAQ:GYRE)’s share price reached a new 52-week low during trading on Friday . The stock traded as low as $6.57 and last traded at $6.6150, with a volume of 61637 shares changing hands. The stock had previously closed at $7.00.

Analyst Ratings Changes

GYRE has been the topic of a number of recent research reports. Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research report on Monday. Wall Street Zen lowered shares of Gyre Therapeutics from a “buy” rating to a “hold” rating in a research report on Saturday, March 14th. Finally, Zacks Research downgraded shares of Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, Gyre Therapeutics has a consensus rating of “Hold” and a consensus target price of $17.00.

Gyre Therapeutics Price Performance

The company has a fifty day moving average price of $7.46 and a 200 day moving average price of $7.66. The company has a market cap of $641.27 million, a PE ratio of -73.09 and a beta of 2.03.

Gyre Therapeutics (NASDAQ:GYRE) last issued its quarterly earnings results on Thursday, March 12th. The company reported $0.04 EPS for the quarter, missing analysts’ consensus estimates of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The company had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. As a group, sell-side analysts predict that Gyre Therapeutics, Inc. will post -0.3 EPS for the current fiscal year.

Insider Transactions at Gyre Therapeutics

In other Gyre Therapeutics news, CEO Ying Luo sold 10,136 shares of the stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total transaction of $81,493.44. Following the transaction, the chief executive officer directly owned 2,565,226 shares in the company, valued at $20,624,417.04. This trade represents a 0.39% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.00% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Dimensional Fund Advisors LP grew its position in Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company’s stock worth $176,000 after acquiring an additional 14,365 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after purchasing an additional 1,941 shares during the period. Barclays PLC boosted its stake in shares of Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after purchasing an additional 5,135 shares during the period. Charles Schwab Investment Management Inc. grew its holdings in shares of Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company’s stock worth $1,194,000 after purchasing an additional 45,772 shares during the last quarter. Finally, State Street Corp increased its stake in shares of Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company’s stock worth $1,428,000 after buying an additional 19,472 shares during the period. Hedge funds and other institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.